Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
When patients progress to the final stage of chronic kidney disease (CKD) and require hemodialysis treatment, they typically have lost so much muscle function that they are no longer physically independent. However, due to disease- and hemodialysis-related muscle catabolism, dietary protein and exercise interventions are only capable to attenuate the decline in physical function of patients on hemodialysis treatment. Therefore, lifestyle interventions to increase muscle function should be implemented before hemodialysis is required. However, it is still a matter of debate whether muscle protein synthesis rates of patients with advanced CKD can be increased with a patient-tailored dietary protein and exercise intervention.Therefore, the current study will assess MPS rates during habitual lifestyle and during an interventional program including dietary protein and exercise in patients with advanced CKD. In addition, we will compare MPS rates during free-living conditions between patients with advanced CKD and healthy controls.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Habitual lifestyle period | No Intervention |
| |
| Exercise training period | Experimental |
|
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Whey protein | Dietary Supplement | Throughout 1 week (either in week 1 or 2), all participants will perform a 1-week resistance type exercise-training program, consisting of two different exercises. Leg press and leg extension exercise will be performed on regular weightlifting machines (Technogym, Rotterdam) at 3 days during the 1-week period (e.g. Monday-Wednesday-Friday). During the resistance exercise training protocol, participants will continue their habitual diet as usual. However, patients with CKD will be provided with a protein supplement following the exercise sessions. |
| Measure | Description | Time Frame |
|---|---|---|
| Muscle protein synthesis rates | Muscle protein synthesis rates as measured by the deuterated water method | 1-week period |
| Measure | Description | Time Frame |
|---|---|---|
| Physical activity levels | as measured by accelerometry | 1-week period |
| Dietary intake (energy/macronutrient) | as measured by dietary diaries |
Not provided
In order to be eligible to participate in this study, a patient with CKD must meet all of the following criteria:
In order to be eligible to participate in this study, a healthy subject must meet all of the following criteria:
1. A potential subject with CKD who meets any of the following criteria will be excluded from participation in this study:
Insulin-dependent diabetes mellitus or two or more oral glucose lowering medications
Active inflammatory disease / malignancies
Uncontrolled hypertension (>160/100mm Hg), unstable angina pectoris, or arrhythmia
Pulmonary disease restricting exercise performance (e.g. COPD)
A history of neuromuscular problems
Cognitive Impairment
Diagnosed GI tract diseases / dysphagia
Allergies to milk proteins / Lactose intolerance
Pregnancy
Hospitalization <1 months prior to study period
Participation in any structured exercise program
Any medications known to affect protein metabolism (i.e. corticosteroids or prescription strength acne medications).
Use of DOAC, vitamin-K-antagonist, or multiple anticoagulants.
Dialysis treatment or previous kidney transplantation
2. A potential healthy subject who meets any of the following criteria will be excluded from participation in this study:
Insulin-dependent diabetes mellitus or two or more oral glucose lowering medications
Active inflammatory disease / malignancies
Uncontrolled hypertension (>160/100mm Hg), unstable angina pectoris, or arrhythmia
Pulmonary disease restricting exercise performance (e.g. COPD)
A history of neuromuscular problems
Cognitive Impairment
Diagnosed GI tract diseases / dysphagia
Allergies to milk proteins / Lactose intolerance
Pregnancy
Hospitalization <1 months prior to study period
Participation in any structured exercise program
Any medications known to affect protein metabolism (i.e. corticosteroids or prescription strength acne medications).
Use of DOAC, vitamin-K-antagonist, or multiple anticoagulants.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Luc JC van Loon, Prof. Dr. | Maastricht University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Maastricht University Medical Center+ | Maastricht | Limburg | 6229ER | Netherlands |
Not yet determined
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D007674 | Kidney Diseases |
| D009133 | Muscular Atrophy |
| ID | Term |
|---|---|
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000067816 | Whey Proteins |
| D055070 | Resistance Training |
| ID | Term |
|---|---|
| D008894 | Milk Proteins |
| D000080224 | Animal Proteins, Dietary |
| D004044 | Dietary Proteins |
| D011506 | Proteins |
Not provided
Not provided
Randomized crossover study (1-week intervention vs. 1-week habitual lifestyle) for both patients with advanced CKD and healthy controls
Not provided
Not provided
Participants will be randomized to either start with the habitual lifestyle period or the exercise training period. All randomization procedures will be executed by an independent researcher. Due to the nature of the intervention, blinding of participants and investigators during the exercise training period is not possible. During the analysis, the research technicians will only receive the participant codes to ensure blinding during analysis of blood, saliva, and muscle 2H-enrichment. Thereafter, an independent researcher will provided a blinded dataset to the research team.
|
|
| 1-week period |
| Leg fat free mass | as measured by DEXA | Baseline |
| Body composition | as measured by BIA | Baseline |
| Type I and II skeletal muscle fiber size | of muscle biopsy of vastus lateralis | Baseline |
| Skeletal muscle mitochondrial bioenergetics | of muscle biopsy of vastus lateralis | Baseline |
| Muscle strength | 1-RM max testing of leg press and leg extension | Baseline |
| Aerobic capacity | VO2-peak test on ergometer | Baseline |
| D052801 | Male Urogenital Diseases |
| D020879 | Neuromuscular Manifestations |
| D009461 | Neurologic Manifestations |
| D009422 | Nervous System Diseases |
| D001284 | Atrophy |
| D020763 | Pathological Conditions, Anatomical |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D012816 | Signs and Symptoms |
| D000602 |
| Amino Acids, Peptides, and Proteins |
| D000067796 | Whey |
| D008892 | Milk |
| D003611 | Dairy Products |
| D005502 | Food |
| D000066888 | Diet, Food, and Nutrition |
| D010829 | Physiological Phenomena |
| D019602 | Food and Beverages |
| D005081 | Exercise Therapy |
| D012046 | Rehabilitation |
| D000359 | Aftercare |
| D003266 | Continuity of Patient Care |
| D005791 | Patient Care |
| D013812 | Therapeutics |
| D026741 | Physical Therapy Modalities |
| D064797 | Physical Conditioning, Human |
| D015444 | Exercise |
| D009043 | Motor Activity |
| D009068 | Movement |
| D009142 | Musculoskeletal Physiological Phenomena |
| D055687 | Musculoskeletal and Neural Physiological Phenomena |